Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Bronchitis - Pipeline Review, H2 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 50 | Code: MRS - 18566


Global Markets Directs, Bronchitis Pipeline Review, H2 2014, provides an overview of the Bronchitiss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bronchitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchitis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Bronchitis
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Bronchitis and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Bronchitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Bronchitis pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Bronchitis
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Bronchitis Overview 6
Therapeutics Development 7
Pipeline Products for Bronchitis - Overview 7
Pipeline Products for Bronchitis - Comparative Analysis 8
Bronchitis - Therapeutics under Development by Companies 9
Bronchitis - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Bronchitis - Products under Development by Companies 12
Bronchitis - Companies Involved in Therapeutics Development 13
DBV Technologies S.A. 13
Hyundai Pharmaceutical Co., Ltd. 14
Mucosis B.V. 15
Myelo Therapeutics GmbH 16
Pacific Therapeutics Ltd. 17
PARI Pharma GmbH 18
Recipharm AB 19
Bronchitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
(pentoxifylline + acetylcysteine) - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
cyclosporine liposomal - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
erdosteine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
HOB-051 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Myelo-001 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
nitric oxide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RSV vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
SynGEM - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Bronchitis - Recent Pipeline Updates 40
Bronchitis - Dormant Projects 43
Bronchitis - Discontinued Products 44
Bronchitis - Product Development Milestones 45
Featured News & Press Releases 45
Jan 23, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants 45
Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine 45
Nov 13, 2012: Pacific Therapeutics Announces Positive Results From Phase I Trial Of PTL-202 46
Aug 22, 2012: Pacific Therapeutics Completes Enrollment In Clinical Trial Of PTL-202 46
Jan 10, 2012: Pacific Therapeutics Provides Update On Development Of Lead Drug Candidate, PTL-202 47
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA 47
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans 48

Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables

Number of Products under Development for Bronchitis, H2 2014 7
Number of Products under Development for Bronchitis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Bronchitis - Pipeline by DBV Technologies S.A., H2 2014 13
Bronchitis - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2014 14
Bronchitis - Pipeline by Mucosis B.V., H2 2014 15
Bronchitis - Pipeline by Myelo Therapeutics GmbH, H2 2014 16
Bronchitis - Pipeline by Pacific Therapeutics Ltd., H2 2014 17
Bronchitis - Pipeline by PARI Pharma GmbH, H2 2014 18
Bronchitis - Pipeline by Recipharm AB, H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Assessment by Combination Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Bronchitis Therapeutics - Recent Pipeline Updates, H2 2014 40
Bronchitis - Dormant Projects, H2 2014 43
Bronchitis - Discontinued Products, H2 2014 44

List of Figures

Number of Products under Development for Bronchitis, H2 2014 7
Number of Products under Development for Bronchitis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Top 10 Targets, H2 2014 22
Number of Products by Stage and Top 10 Targets, H2 2014 22
Number of Products by Top 10 Mechanism of Actions, H2 2014 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 24
Number of Products by Top 10 Routes of Administration, H2 2014 26
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 26
Number of Products by Top 10 Molecule Types, H2 2014 28
Number of Products by Stage and Top 10 Molecule Types, H2 2014 28

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing